30 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 34 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 34 | Completed 30, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 3, Not yet recruiting 1 |
Follow Roflumilast: new trials by email Literature Review of Roflumilast trials Research Report on Roflumilast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients Placebo, Roflumilast - NAFLD (Nonalcoholic Fatty Liver Disease) | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 60 | 2026-11-01 | 2026-10-28 |
| Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients Fluoxetine, Roflumilast, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Tanta University | 60 | 2025-03-01 | 2026-05-04 |
| Roflumilast Versus Methotrexate in Psoriasis Roflumilast, Methotrexate - Psoriasis | Phase 2 / Phase 3 | Completed | Cairo University | 30 | 2023-01-09 | 2023-05-16 |
| Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy Alpha lipoic acid, Roflumilast - Type 2 Diabetes (Adult Onset), Diabetic Neuropathies | Phase 3 | Completed | Tanta University | 60 | 2022-08-01 | 2023-11-22 |
| A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) CHF6001 1600µg, CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 3973 | 2021-07-12 | 2026-02-02 |
| The Possible Effects of Roflumilast on Obesity Related Disorders Roflumilast, placebo - Obesity, PreDiabetes | Phase 3 | Completed | Tanta University | 66 | 2021-05-01 | 2022-04-05 |
| Possible Role of Roflumilast in Diabetic Nephropathy Roflumilast, Placebo - Diabetic Nephropathies | Phase 3 | Unknown | Tanta University | 48 | 2021-03-10 | 2021-02-16 |
| Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% - Atopic Dermatitis Eczema | Phase 3 | Completed | Arcutis Biotherapeutics, Inc. | 1220 | 2021-02-25 | 2025-12-23 |
| Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Topical roflumilast - Chronic Plaque Psoriasis | Phase 3 | Completed | Arcutis Biotherapeutics, Inc. | 337 | 2020-02-12 | 2026-09-09 |
| Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial Roflumilast, Azithromycin - Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis | Phase 3 | Completed | Johns Hopkins University | 1032 | 2020-02-11 | 2026-08-21 |
| Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Roflumilast 0.3% cream, Vehicle Cream - Chronic Plaque Psoriasis | Phase 3 | Completed | Arcutis Biotherapeutics, Inc. | 439 | 2019-12-20 | 2022-12-07 |
| Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis Roflumilast, Placebo - Exacerbation Copd, Bronchiectasis | Phase 3 | Completed | Prince of Songkla University | 40 | 2015-01-01 | 2019-10-10 |
| Enhancement of Corticosteroid Efficacy in COPD Theophylline, Roflumilast - COPD | Phase 3 | Completed | UConn Health | 13 | 2014-12-01 | 2018-06-19 |
| Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD Roflumilast, Roflumilast Placebo, Standard of Care COPD Treatment - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | AstraZeneca | 1323 | 2014-05-01 | 2017-04-20 |
| Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization Roflumilast, Placebo - COPD | Phase 3 | Completed | Temple University | 68 | 2013-11-01 | 2020-03-12 |
| Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease Roflumilast, Placebo - COPD, Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | AstraZeneca | 158 | 2012-02-01 | 2019-11-29 |
| A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore: Roflumilast, Placebo, Salbutamol - COPD | Phase 3 | Completed | AstraZeneca | 626 | 2011-03-01 | 2017-02-01 |
| Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128) Roflumilast, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | AstraZeneca | 743 | 2007-01-01 | 2016-12-05 |
| Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127) Roflumilast, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | AstraZeneca | 933 | 2006-04-01 | 2016-12-14 |
| Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125) Roflumilast, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | AstraZeneca | 1568 | 2006-03-01 | 2016-11-07 |
Showing 20 of 34. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (18) · Asthma (6) · Bronchitis, Chronic (2) · Bronchiectasis (1) · Depressive Disorder, Major (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Nephropathies (1) · Diabetic Neuropathies (1) · Emphysema (1) · Hyperglycemia (1) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1) · Prediabetic State (1) · Psoriasis (1)
AstraZeneca (20) · Tanta University (5) · Arcutis Biotherapeutics, Inc. (3) · Cairo University (1) · Chiesi Farmaceutici S.p.A. (1) · Johns Hopkins University (1) · Prince of Songkla University (1) · Temple University (1) · UConn Health (1)
United States (15) · Canada (9) · France (8) · Spain (8) · United Kingdom (8) · Germany (7) · Poland (7) · South Africa (7) · Austria (6) · Egypt (5) · Hungary (5) · Italy (5) · Russia (5) · Japan (4) · Argentina (3)
David Berk, MD (2) · Gerard J Criner, MD (1) · Hisham M Elnahhas, Pharm D (1) · Jerry Krishnan, MD, PhD (1) · Kanung Saejiam, MS (1) · Mostafa Bahaa (1) · Nausherwan Burki (1) · Robert Wise, MD (1) · Sara M Zayed (1)
PMID 20102307, PMID 28419462, PMID 26498386, PMID 26612545, PMID 19716960, PMID 19716961, PMID 21272339, PMID 23117188, PMID 24120253, PMID 24135893, PMID 26456372, PMID 29797235, PMID 30224319, PMID 36125472, PMID 36422852, PMID 41134450, PMID 41256904
2005 (1), 2023 (1)